Aquestive Therapeutics, Inc. - AQST
Insiders (Form 4) · last 180 days · showing up to 200 transactions
· Form 144 is shown in the SEC filings tab
· Updating…
Visible: 0
Transaction codes:
P = Open-market purchase ·
S = Open-market sale ·
A = Grant/award ·
M = Exercise/conversion of derivative ·
G = Gift ·
F = Tax withholding ·
J = Other ·
A/D:
A = Acquired (buy/receive) ·
D = Disposed (sell/give)
| Filed | Owner | Title | Code | A/D | Shares | Price | Value | Shares after | SEC |
|---|---|---|---|---|---|---|---|---|---|
| Apr 13, 2026 | President and CEO | A | A | 293,100.0 | 0.0 | 0.0 | 293,100.0 | View | |
| Apr 13, 2026 | Chief People Officer | A | A | 60,000.0 | 0.0 | 0.0 | 60,000.0 | View | |
| Apr 13, 2026 | Chief Operating Officer | A | A | 60,000.0 | 0.0 | 0.0 | 60,000.0 | View | |
| Apr 13, 2026 | SVP, Chief Financial Officer | A | A | 82,500.0 | 0.0 | 0.0 | 82,500.0 | View | |
| Apr 13, 2026 | Chief Commercial Officer | A | A | 67,500.0 | 0.0 | 0.0 | 67,500.0 | View | |
| Apr 13, 2026 | Corporate Secretary | A | A | 82,500.0 | 0.0 | 0.0 | 82,500.0 | View | |
| Mar 11, 2026 | Chief Development Officer | A | A | 50,000.0 | 0.0 | 0.0 | 50,000.0 | View | |
| Mar 11, 2026 | Chief Development Officer | A | A | 50,000.0 | 0.0 | 0.0 | 100,000.0 | View | |
| Mar 11, 2026 | Chief Operating Officer | A | A | 42,500.0 | 0.0 | 0.0 | 42,500.0 | View | |
| Mar 11, 2026 | Chief Operating Officer | S | D | 45,791.0 | 4.173 | 191,085.84 | 274,980.0 | View | |
| Mar 11, 2026 | Chief Operating Officer | A | A | 80,000.0 | 0.0 | 0.0 | 320,771.0 | View | |
| Mar 11, 2026 | Chief Commercial Officer | A | A | 42,500.0 | 4.29 | 182,325.0 | 42,500.0 | View | |
| Mar 11, 2026 | Chief Commercial Officer | S | D | 15,741.0 | 4.173 | 65,687.19 | 241,117.0 | View | |
| Mar 11, 2026 | Chief Commercial Officer | A | A | 75,000.0 | 0.0 | 0.0 | 256,858.0 | View | |
| Mar 11, 2026 | Chief Financial Officer | A | A | 70,000.0 | 0.0 | 0.0 | 70,000.0 | View | |
| Mar 11, 2026 | Chief Financial Officer | S | D | 58,254.0 | 4.173 | 243,093.94 | 376,112.0 | View | |
| Mar 11, 2026 | Chief Financial Officer | A | A | 95,000.0 | 0.0 | 0.0 | 434,366.0 | View | |
| Mar 11, 2026 | SVP, Regulatory Affairs | A | A | 75,000.0 | 4.29 | 321,750.0 | 75,000.0 | View | |
| Mar 11, 2026 | SVP, Regulatory Affairs | S | D | 25,311.0 | 4.173 | 105,622.8 | 274,867.0 | View | |
| Mar 11, 2026 | SVP, Regulatory Affairs | A | A | 100,000.0 | 0.0 | 0.0 | 300,178.0 | View | |
| Mar 11, 2026 | Chief Legal Officer | A | A | 50,000.0 | 4.29 | 214,500.0 | 50,000.0 | View | |
| Mar 11, 2026 | Chief Legal Officer | S | D | 40,102.0 | 4.173 | 167,345.65 | 442,879.0 | View | |
| Mar 11, 2026 | Chief Legal Officer | A | A | 80,000.0 | 0.0 | 0.0 | 482,981.0 | View | |
| Mar 11, 2026 | President and CEO | A | A | 523,000.0 | 4.29 | 2,243,670.0 | 523,000.0 | View | |
| Mar 11, 2026 | President and CEO | S | D | 180,677.0 | 4.173 | 753,965.12 | 1,004,753.0 | View | |
| Mar 11, 2026 | President and CEO | A | A | 262,000.0 | 0.0 | 0.0 | 1,185,430.0 | View | |
| Mar 11, 2026 | Chief People Officer | A | A | 42,500.0 | 4.29 | 182,325.0 | 42,500.0 | View | |
| Mar 11, 2026 | Chief People Officer | S | D | 29,814.0 | 4.173 | 124,413.82 | 338,509.0 | View | |
| Mar 11, 2026 | Chief People Officer | A | A | 80,000.0 | 0.0 | 0.0 | 368,323.0 | View | |
| Mar 11, 2026 | Chief Medical Officer | A | A | 50,000.0 | 4.29 | 214,500.0 | 50,000.0 | View | |
| Mar 11, 2026 | Chief Medical Officer | A | A | 75,000.0 | 0.0 | 0.0 | 75,000.0 | View | |
| Dec 05, 2025 | Chief People Officer | A | A | 20,000.0 | 0.0 | 0.0 | 288,323.0 | View | |
| Dec 04, 2025 | SVP, Regulatory Affairs | F | D | 2,083.0 | 5.93 | 12,352.19 | 200,178.0 | View | |
| Nov 12, 2025 | Chief Development Officer | A | A | 50,000.0 | 0.0 | 0.0 | 50,000.0 | View | |
| Nov 12, 2025 | Chief Development Officer | A | A | 50,000.0 | 0.0 | 0.0 | 50,000.0 | View |